South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market 
US and Japan Fast-Track $550 Billion Strategic Investment Initiative 
BOJ Governor Signals Gradual Rate Hikes as Japan’s Inflation Nears 2% Target 
Gold Price Breaks $4,500 as Safe-Haven Demand and Rate Cut Bets Fuel Rally 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Platinum Surges to Record High as Supply Crunch and Policy Shift Drive Historic Rally 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
China Revises 2024 GDP Lower After Final Review, Eyes Growth in 2025 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy 
U.S. Stock Index Futures Steady After S&P 500 Hits Record on Strong Economic Data 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
